| Details |
| Disease Name | Glioblastoma |
| Nocoding RNA Name | hsa-miR-181b |
| Expression Pattern | down-regulated |
| Species | Homo sapiens |
| Detection Methods | Real-time qPCR,Luciferase Reporter Assay,Western Blot etc. |
| Target | RhoA |
| Tissue | brain(brain tumor tissue) |
| Treatment | temozolomide |
| PubMed ID | 24573637 |
| Year | 2014 |
| Detail Description | lower expression of miR-181a/b/c/d subunits contributes to astrocytoma tumorigenesis, and their overexpression could inhibit the invasive proliferation of glioblastoma cells by targeting Rap1B mediated cytoskeleton remodeling and related molecular(Cdc42, RhoA and N-cadherin) changes, suggesting that miR-181 was a critical regulator and might be an important target for glioblastoma treatment. TMZ as a standard chemotherapeutic agent for GBM inhibited the Rap1B expression and actin cytoskeleton remodeling to exert its cell killing by upregulating miR-181a/b/c/d subunits; conversely, each miR-181a/b/c/d subunit enhanced the chemosensitivity of TMZ in glioblastoma cells. |
NSDNA: The Nervous System Disease NcRNAome Atlas
Contact wanglh211@163.com for inquiries and feedback
© All right reserved 2016